The impact of a genomic assay (Oncotype DX) on adjuvant treatment recommendations in early breast cancer

Medical Journal of Australia

Volumn 199, Issue 3, 2013, Pages 205-208

  de Boer, Richard H ^a,b   Baker, Caroline ^c   Speakman, David ^d   Chao, Calvin Y ^e   Yoshizawa, Carl ^e   Bruce Mann, G ^f  

^a ROYAL MELBOURNE HOSPITAL   (United States)

^b ROYAL WOMEN'S HOSPITAL   (United States)

^c Austin Health   (United States)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

^e Genomic Health   (United States)

^f UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; ASSAY; AUSTRALIA; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RECURRENCE; CLINICAL DECISION MAKING; CONTROLLED STUDY; EARLY CANCER; ESTROGEN RECEPTOR NEGATIVE BREAST CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GENOMIC ASSAY; HORMONAL THERAPY; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; NODE NEGATIVE BREAST CANCER; NODE POSITIVE BREAST CANCER; PATIENT COMPLIANCE; PROGESTERONE RECEPTOR NEGATIVE BREAST CANCER; PROGESTERONE RECEPTOR POSITIVE BREAST CANCER; SCORING SYSTEM;

EID: 84881275239     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja12.11334     Document Type: Article

References (20)

1. Australian Institute of Health and Welfare. Cancer in Australia 2010: an overview. Canberra: AIHW, 2010. (AIHW Cat. No. CAN 56; Cancer Series No. 60.) http://www.aihw.gov.au/ publication-detail/?id=6442472459 (accessed Feb 2013).
2. Ernst MF, Voogd AC, Coebergh JW, Roukema JA. Breast carcinoma diagnosis, treatment, and prognosis before and after the introduction of mass mammographic screening. Cancer 2004; 100: 1337-1344.
3. Lester S, Cotran RS. The breast. In: Cotran RS, Kumar V, Collins T, editors. Robbins pathologic basis of disease. 6th ed. Philadelphia, Pa: WB Saunders Company, 1999: 1093-1119.
4. Early Breast Cancer TrialistS' Cooperative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998; 352: 930-942.
5. Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009; 20: 1319-1329.
6. McEvoy SP, Ingram DM, Byrne MJ, et al. Breast cancer in Western Australia: clinical practice and clinical guidelines. Med J Aust 2004; 181: 305-309.
7. White V, Pruden M, Giles G, et al. The management of early breast carcinoma before and after the introduction of clinical practice guidelines. Cancer 2004; 101: 476-485.
8. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-2826.
9. Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010; 11: 55-65.
10. Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a Trans ATAC study. J Clin Oncol 2010; 28: 1829-1834.
11. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24: 3726-3734.
12. Albanell J, González A, Ruiz-Borrego M, et al. Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer. Ann Oncol 2012; 23: 625-631.
13. Blohmer JU, Rezai M, Kümmel S, et al. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting. J Med Econ 2013; 16: 30-40.
14. Klang SH, Hammerman A, Liebermann N, et al. Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization. Value Health 2010; 13: 381-387.
15. Lo SS, Mumby PB, Norton J, et al. Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 2010; 28: 1671-1676.
16. Oratz R, Kim B, Chao C, et al. Physician survey of the effect of the 21-gene recurrence score assay results on treatment recommendations for patients with lymph node-positive, estrogen receptor-positive breast cancer. J Oncol Pract 2011; 2: 94-99.
17. Kamal AH, Loprinzi CL, Reynolds C, et al. Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score. Oncologist 2011; 16: 1359-1366.
18. National Breast Cancer Centre. Multidisciplinary meetings for cancer care: a guide for health service providers. Camperdown, NSW: NBOCC, 2005.
19. Cuzick J, Dowsett M, Pineda S, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol 2011; 29: 4273-4278.
20. Dowsett M, Nielsen TO, A'Hern R, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst 2011; 103: 1656-1664.